Egyptian

Pharmaceutical
Market Research
2022-2027
 Pharmaconex Market Research 1

Table of Contents

Part 01 Egypt General Overview 03

Part 02 Egyptian Pharmaceutical Market Overview 08
Part 03 Regulatory Bodies in Egyptian Pharmaceutical Market 23
Part 04 Egyptian Pharmaceutical Market Dynamics 27
Part 05 Egyptian APIs Market Forecast 31
 Pharmaconex Market Research 2

Part. 1
Egypt General Overview
Egypt General Overview Pharmaconex Market Research 3

Location
Egypt is located in the northeast of Africa and the west of Asia. It is located in the transportation
hub of the three continents of Europe, Asia and Africa. It is the country with the largest population
in North Africa and Arab countries and a powerful country in economy, science and technology.

Civilization
One of the world’s earliest and greatest civilizations, with a unified kingdom first
surfacing around 7000 years B.C.

People Habits
• Egyptians are religious people, with more than 90% Muslims, 10% Christians.
• Famous profusions as Engineering, Medical field and agricultures.

Pharmaceutical Market
• Egypt has a strong manufacturing industry and is the largest producer
and consumer of pharmaceuticals in the MENA region.
• Behind only Saudi Arabia (USD 8.5 billion) within MEA, Egypt’s pharma
market has consolidated its position as the prime destination outside of
the Gulf with USD 6.3 billion in value in 2021.
Egypt General Overview - Population Pharmaconex Market Research 4

Egyptian Population Forecast

Million • The current population of Egypt is estimated
at more than 106 million, which is the most
160 populated country in middle east.
140.4
140 130.3 • Egypt population is equivalent to 1.31% of the
120.8 total world population.
120 111.7
102.3 • Egypt ranks number 14 in the list of countries
100 91.5
(and dependencies) by population in the world.
80 • The population density in Egypt is 103 per Km2
(266 people per mi2).
60
• The total land area is 995,450 Km2 (384,345 sq.
40 miles).
20 • 43.0 % of the population is urban.

0 • The median age in Egypt is 24.6 years.

2015 2020 2025 2030 2035 2040 Year

Source: Worldometer
Egypt General Overview - Diseases Pharmaconex Market Research 5

Top 10 Causes of Death About 70 percent of deaths in Egypt are

due to chronic diseases including diabetes,
heart disease, stress and cancer according to the
World World Health Organization official, Randa Abul-
Causes of Death
Rank Naga. Epidemiological studies by WHO have shown
that non communicable diseases, such as cancer,
Coronary Heart Disease 15 cardiovascular diseases (especially ischemic heart disease),
Liver Disease 1 diabetes and mental health diseases, are the main causes
Stroke 110 of morbidity and mortality in the region.
Liver Cancer 2
Hypertension 35 • Cardiovascular disease
Kidney Disease 46
In Egypt, cardiovascular disease accounts for about
Influenza and Pneumonia 99
40% of the total population, and is currently the
Diabetes Mellitus 92
main cause of death in Egypt. Cardiovascular
Lung Disease 100
disease is a chronic disease that requires
Breast Cancer 33
a long treatment time and requires the
Source: World Health Organization use of a variety of different drugs. The
large base of patients can promote
the rapid growth of the Egyptian
pharmaceutical industry.
Egypt General Overview - Diseases Pharmaconex Market Research 6

• Cancer • Infectious disease • Obesity and type 2

Liver cancer is the most common hepatitis C diabetes
cancer in men, followed by
Egypt had the highest prevalence They’re becoming increasingly
bladder, lung and non Hodgkin’s
of hepatitis C virus (HCV) infection prevalent worldwide, and both are
lymphoma. Breast cancer is the
in the world as a result of the associated with increased cancer
most common malignancy in
prevalence of schistosomiasis incidence and mortality. Egypt has
women, followed by liver cancer,
and its mass treatment by unsafe the highest obesity rate among
non Hodgkin’s lymphoma and
intravenous injections in the 1950s the world‘s 20 most populous
brain cancer.
and 1960s. countries, and the prevalence
Thus, it is not surprising that liver of diabetes in Egyptian adults is
cancer, mainly hepatocellular around 15.6%.
carcinoma (HCC, which constitutes
about 70.5% of all liver cancers),
was the most common cancer
among men (33.6%) and was the
second-most common cancer
among women (13.5%) after breast
cancer in the National Cancer
Registry Program.
Egypt General Overview - Diseases Pharmaconex Market Research 7

Diseases
One of the main drivers of the growth of the Egyptian pharmaceutical market
is the aging population and chronic diseases. The emergence of respiratory
diseases, heart diseases and cardiovascular diseases, especially in promoting the
development of high-value prescription drugs in Egypt.

Epidemiological studies by WHO have shown that non communicable

diseases are the main cause of morbidity and mortality in Egypt. Health
problems related to young people are increasingly reflecting problems in
more developed countries, such as the prevalence of mental illness. There are
several mainstream diseases will increase significantly.

• Chronic diseases, such as

chronic respiratory diseases (+ 58%)
• Cancer (+ 47%)
• Ischemic heart disease (+ 23%)
• Musculoskeletal diseases (+ 46%)
• Mental and behavioral illness (+ 47%)
• Cardiovascular disease (+ 20%)
 Pharmaconex Market Research 8

Part. 2
Egyptian Pharmaceutical Market Overview
Egyptian Pharmaceutical Market Overview - Market Position in MEA Pharmaconex Market Research 9

MEA Pharma Market by Country

The overall MEA pharmaceutical market
reached USD 30 billion in September 2021 and,
according to IQVIA’s quarterly report published in
January, the region’s market is forecasted to reach
USD 47 billion in 2022.

Many large markets have experienced slow

growth due to covid-19 lockdowns. In September of
2021, Egypt pharma market is valued at $6.3bn with a
growth rate of 16.1% over last year. The rest of the top 5
includes Saudi Arabia (8.5) , South Africa (3.7), United
Arab Emirates (2.8) and Algeria (2.4).

According to QVIA, local companies account for

56% of the market in sales, while multinationals have
44%. In fact, the fast growth of region’s market can be
highly attributed to Egypt, beacause Eva Pharma and
Sedico/Acdima are two Egyptian companies of the top
10 fastest growing companies in MEA.
Source: IQVIA; PHARMA BOARDROOM
Egyptian Pharmaceutical Market Overview - APIs Market Pharmaconex Market Research 10

APIs Market Egypt APIs Market Size and Growth Rate (2017-2022)

2650.00 2602.73 8.00%

The production of most APIs is carried out 2600.00
6.00%
2550.00
by local pharmaceutical companies. However, 2500.00 2431.18 2452.63 4.00%
Egypt’s pharmaceutical market has a relatively 2450.00

short development time, and in the late 1980s 2400.00

2350.10 2330.29
2.00%
2350.00
and early 1990s, the pharmaceutical market 2300.00
2290.77 0.00%

developed rapidly. However, after entering 2250.00 -2.00%

the 21st century, the development of Egypt’s 2200.00

-4.00%
2150.00
pharmaceutical market began to stagnate. 2100.00 -6.00%
2017 2018 2019 2020 2021 2022

Revenue (M USD) Growth Rate

With the end of the transition period of WTO
accession, the Egyptian government had to
implement the TRIPS agreement and open up Source: Secondary Sources, Expert Interviews and WK
the pharmaceutical market, which faced a huge Information Research, 2022
survival crisis for the domestic pharmaceutical
companies in Egypt. It can be seen that the The in-out volume is as high as 90%. Mainly from
domestic API manufacturing capacity in Egypt Europe and the United States and other countries,
is relatively weak, and the market is highly cheap APIs are mainly supplied by China and India and
dependent on APIs produced in other regions. other Asia country.
Egyptian Pharmaceutical Market Overview - Export Status Pharmaconex Market Research 11

Export Status
However, the government encourages
360M
exports and reduces the trade deficit.
340M
Therefore, although the export base is low, the
320M export growth is expected to be faster than
300M that of Egyptian drug imports. Most exports will
continue to target other Middle East and North
280M
African markets, with a focus on Saudi Arabia,
260M the United Arab Emirates, Iraq, Sudan and
240M Jordan.
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
The Minister of health of Egypt announced
Source: COMTRADE
that many pharmaceutical production plants
Egypt Exports of pharmaceutical products was US are still under construction, many of which
$312.63 Million during 2021, according to the United will be built in industrial areas throughout the
Nations COMTRADE database on international trade. country. Exporting generic drugs is the main
Egypt Exports of pharmaceutical products - data, way for Egyptian companies to earn long-term
historical chart and statistics - was last updated on profits, especially in maintaining low prices,
August of 2022. which is very competitive.
Egyptian Pharmaceutical Market Overview - Drugs Pharmaconex Market Research 12

Drugs

Egypt’s pharmaceuticals market

reached about £54bn in the first half,
up about 11% on last year. The top 100
selling products accounted for about
$17 billion in sales, about 32% of the
total sales.

• Controloc ranked toppest selling

product for the first time.
• The sales of hibiotic was close to 1
billion pounds, ranking No. 2.
• Panadol ranked No. 3 in this semster.

Source: Bepac
Egyptian Pharmaceutical Market Overview - Medical Expenditure Pharmaconex Market Research 13

Medical Expenditure
Health care expenditure (percentage of GDP) 4.7 %
Per capita medical expenditure (PPP) 582 international dollars
General government expenditure on health as a share of current health expenditure 27.8 %
Percentage of total government medical expenditure to total government expenditure 4.7 %
Out of pocket expenditure as a share of current health expenditure 62.7 %
Total health care expenditure 12,357 million US dollars
Social health insurance as a share of current health expenditure 7%
Voluntary health insurance as a share of current health expenditure 6.9 %
Per capita expenditure on government health care 36 US dollars
Per capita expenditure on general health administration at purchasing power parity (NCU/ USD) 176 US dollars
Private health care expenditure (the percentage) 71.2 %
 Egyptian Pharmaceutical Market Overview Pharmaconex Market Research 14

Supply and Demand

Egypt has a strong domestic pharmaceutical industry, with about 200 pharmaceutical
companies, of which less than 10 are multinational companies with local production
bases.
Egypt has the largest drug manufacturing base in the Middle East & North Africa,
accounting for nearly 30% of the regional market.
The drugs produced in Egypt can meet nearly 93% of its local demand for
medicine, with 7% consisting of highly specialized pharmaceuticals that are
not locally produced.
5% of domestic drugs are exported to the Arab region, Africa and some
European countries.
Multinational corporations account for nearly 40% of local sales
through domestic manufacturing, and about 35% through licensing
agreements, while the remaining percentage represents generic
medicines produced by local companies.
In Egypt, the hospital channel is carrying the load and accounts
for 40% of the country’s sales.
 Egyptian Pharmaceutical Market Overview - Supply & Demand Pharmaconex Market Research 15

Egypt spends a lot on medicine. 56% of health spending. Drug purchases at pharmacies
account for nearly half of out-of-pocket payments. Drug prices are administered by the
Ministry of Health’s Central Agency for Pharmaceutical Affairs (CAPA), which sets mandatory
retail prices for drugs.
Almost all raw materials for local manufacturing need to be imported. Egypt imports
about $600 million in finished medicines and $1.8 billion in active ingredients annually.
Multinational companies set up factories locally, but 15-20% of medicines are imported
and 80-85% are produced locally. In Egypt, about 70% of medicines are generic and
domestically produced.
Given the lack of a comprehensive health-insurance system in Egypt, the
pharmaceuticalsales are based on out-of-pocket expenditures as consumers
find self-medicating to be the cheapest form of treatment. Pharmaceutical
sales are divided into prescription drugs and over-the-counter (OTC) drugs.
Sales of patented drugs will outgrow that of generic drugs due to the
domestic industry’s heavy reliance on importing raw materials, which
have surged in the past year. It should be noted, however, that the
market could eventually shift favour towards generics, given their
cheaper price tags, and the government’s willingness to maintain
cost-containment measures.

Source: Secondary Sources, Expert Interviews and WK Information

Egyptian Pharmaceutical Market Overview - Market Segmentation Pharmaconex Market Research 16

Market Segmentation
Classification of
Pharmaceutical Enterprises
85
90
80
11% 70
70
60
7%
50
40
30
82% 30
20
10 8

0
Private Company Public Corporation

Private Company Public Corporation Joint Venture Regional Agent Market Share
Egyptian Pharmaceutical Market Overview - Sales Channel Pharmaconex Market Research 17

Sales Channel
Drug Distribution Pharmaceutical Retail
There are two channels for the sale of drugs Pharmacies deal with foreign companies, state-
in Egypt: Consignment and self-supporting. The owned enterprises and wholesalers. Although there
main channel is the sale of drugs through the sales are a few chain stores, most pharmacies are public.
network of drug distribution companies. For example, El-Ezaby, which was founded in 1975
and belongs to Multipharma group, aims to become
At present, the largest drug distribution company a leading pharmacy chain in the Middle East.
in Egypt is Egydrug, a state owned Egyptian drug
company, and UCP, a private joint distribution Other chain stores include Misr Pharmaceuticals
company. and Seif Pharmaceuticals, which are part of the Seif
Group and mainly target high-income people.
Egydrug has the largest sales network in China,
with sales points all over the country. And the
company pays the manufacturer in cash, while
private companies generally need to sell on credit.
Although the agency fee charged by the state is
higher than that charged by the private sector,
many companies prefer to use Egydrug as an agent.
Egyptian Pharmaceutical Market Overview - Pharmaceutical Companies Pharmaconex Market Research 18

Pharmaceutical Companies
Domestic: leading local manufacturers include Eipico, Amoun
Pharma, Pharco, MUP and Sedico. Few local pharmaceutical
manufacturers in Egypt are completely state-owned, while the
rest are partially or completely privatized. Public production is
represented by HoldiPharma.

Abroad: leading multinational companies such as Pfizer,

GlaxoSmithKline and AstraZeneca are planning to expand their
local businesses. The current market leaders with production
facilities include Bristol Myers Squibb, GlaxoSmithKline, Novartis
and Pfizer. Other leading multinational companies in the market
include Servier in France and Johnson & Johnson in the United
States, Lilly and Merck.

Although many multinational companies are active in the

Egyptian market, the latest report shows that few multinational
companies produce directly. Many people will import or license
drugs from local manufacturers. Multinational companies
supply about two-thirds of the market through direct local
manufacturing or licensing agreements. Due to the wide variety
of products, local and foreign companies tend to specialize,
which makes the Egyptian drug market highly fragmented.

Source: Bepac
Egyptian Pharmaceutical Market Overview - Local Manufacturers Pharmaconex Market Research 19

Local Manufacturers

Pharco Pharmaceuticals is the founder of the corporation and is the second private Egyptian shareholding
pharmaceutical company established in 1984. It started production in 1987 formulating, producing and
marketing about 450 brands, generics, branded generics and licensed products to date.
Pharco Pharmaceuticals has scientific offices; KSA, Yemen, UAE, Bahrain, Lebanon, Libya and Romania and
exports to 50+ countries. Throughout the years Pharco Pharmaceuticals has created several brands which have
become market leaders in both local and international markets; Gratisovir 400mg, Rani effervescent, Fawar
Fruit, Ciprofar 500 MG tablets, Spasmo Digestin, Delcophen amp, Royal jelly, Uricol effervescent, Urinex caps,
Bilichol caps, Mirazid and Baby Drink. Currently a major cardiovascular line is up to date.

APC (Amoun) is the largest domestic pharmaceutical manufacturer in Egypt and

the domestic company with the highest income, ranking third overall. The company
currently has five branches in Egypt, producing human and veterinary medicine
products and nutritional supplements. APC is the first private drug company
established in the country to import and distribute drugs.
APC’s product portfolio includes anesthetics, analgesics, gastrointestinal drugs,
endocrine drugs, topical preparations, cardiovascular drugs, vitamins and minerals.
APC also aims to increase its exports, aiming to become “Egypt’s leading drug
exporter”.
Egyptian Pharmaceutical Market Overview - Local Manufacturers Pharmaconex Market Research 20

EIPICO is currently one of the leading Egyptian pharmaceutical companies, in

terms of production and sales, in the local market. It is the leading company in
pharmaceutical exports, capturing a 21% share of the total Egyptian pharmaceutical
export market.

EIPICO produces antibiotics, antifungal drugs, dysentery drugs, antihistamines,

antimalarial drugs, blood substitutes, antihypertensive drugs and cardiovascular
drugs, central nervous system (CNS) drugs, dermatological treatment, endocrine and
ophthalmic treatment, and steroid antiinflammatory drugs.

EVA Pharma has been established since 1997. It is one of the leading
pharmaceutical Egyptians companies in MENA region that is built on
the heritage of Les Laboratories Delta, the second oldest pharmaceutical
Egyptian company. Recently, EVA Pharma becomes one of the leading
branded generic pharmaceutical manufacturers in the MENA region with
a CAGR (Compound Annual Growth Rate) of 22.5% over the last three years
enabling EVA Pharma to be one of the fastest-growing pharmaceutical
companies in the region.
Egyptian Pharmaceutical Market Overview - Local Manufacturers Pharmaconex Market Research 21

MUP (Medical Union pharmaceuticals), one of the largest domestic

pharmaceutical manufacturers in Egypt. The pharmaceutical alliance
pharmaceutical company also has a representative office in Kazakhstan,
indicating its ambition for the Commonwealth of Independent States.
Medical Union pharmaceuticals manufactures and distributes drugs,
cosmetics and special foods in Egypt and abroad.
Medical Union pharmaceuticals is mainly concentrated in the local market
of Egypt, and most of its sales are carried out in the local market, while less
through public sector bidding.

SEDICO is one of the most outstanding local companies, focusing

on generic drugs, but it also has three patented products in its
product portfolio, and is one of the leading insulin manufacturers.
SEDICO’s product portfolio includes analgesics,
antihistamines and nasal congestion drugs, antidepressants
and cardiovascular drugs.
Egyptian Pharmaceutical Market Overview - Local Manufacturers Pharmaconex Market Research 22

Manapharma, is considered one of the top and oldest companies in Egypt working as
agent and exclusively representing many international API companies from the US,
Europe and Asia over the past 35 years. In this regards, Manapharma supports and
supply the majority of local pharmaceutical finished products manufacturers in Egypt
with APIs and Excipients.

Chemical Maker is a leading company working in the Egyptian

market since 2005. The company is a marketing company in the field
of pharmaceutical market. They are supporting our customer with
providing the Active pharma ingredients ( API ), and chemical Reagents
used in their labs for the analysis. Their suppliers are all GMP certified
and mostly have DMF, USFDA, and CEP.
 Pharmaconex Market Research 23

Part. 3
Regulatory Bodies in Egyptian Pharmaceutical Market
Regulatory Bodies in Egyptian Pharmaceutical Market Pharmaconex Market Research 24

Regulatory Bodies
The regulatory framework leading
the pharmaceutical industry in
Egypt has been entirely restructured
according to the Egyptian Law
No. 151 of 2019, which declared the
establishment of the Egyptian Drug
Authority (EDA) as its own entity and
the Egyptian Authority for Unified
Procurement, Medical Supply and
Technology Management as a
separate economic unit , aiming for
conceptualizing, developing, and
strengthening the healthcare system
and pharmaceutical industry in Egypt.

Source: The Pharma Letter

With an ambitious target of boosting the pharmaceutical industry in Egypt,
the new Egyptian government has issued a package of laws to improve the
pharmaceutical sector in Egypt. Nevertheless, additional regulations are still
necessary and important to implement.
 Regulatory Bodies in Egyptian Pharmaceutical Market - EDA Pharmaconex Market Research 25

EDA
• The Egyptian Drug Authority (EDA) is established as a public service authority affiliated to the Prime Minister to be responsible
for all drug related matter.
• EDA will be the regulatory authority responsible solely for the registration, licensing, inspection and supervision of all
pharmaceutical and cosmetic products, medical equipment and raw materials used in their manufacturing.

EDA has replaced following entities:

• National Organization for Drug Control and Research (NODCAR).
• National Organization for Research and Control of Biological (NORCB).
• Central Administration of Pharmaceutical Affairs (CAPA) in relation to the registration and licensing or pharmaceutical products.
 Regulatory Bodies in Egyptian Pharmaceutical Market - EDA Pharmaconex Market Research 26

The main responsibilities of EDA will be, among others, the following:
Issuance of the necessary licenses for all pharmaceutical entities.
Issuance of the operation licenses for factories of pharmaceutical products and
medical equipment.
Licensing private laboratories that are working in the pharmaceutical field.
Examination of all pharmaceutical, biological products like medicines, cosmetics,
insecticides, vaccines, serums, pharmaceutical devices, tools, medical lenses,
diagnostic indicators in order to insure their quality, safety, effectiveness and
compliance with the approved.
Setting the rules and procedures for importation, exportation and pricing of all
pharmaceutical products and medical equipment.
Customs release of all imported pharmaceutical products and medical equipment.
Licensing locally manufactured products and equipment.
Issuance of the Egyptian Pharmacopeia.
Inspection of all pharmaceutical entities and their officers and taking necessary
legal actions against violations.
 Pharmaconex Market Research 27

Part. 4
Egyptian Pharmaceutical Market Dynamics
Egyptian Pharmaceutical Market Dynamics - Opportunities Pharmaconex Market Research 28

Opportunities
1 Rapid population growth and urbanization. From 1986
to 2022, the population of Egypt more than doubled, from 48
million to 106 million, ranking 14th in the world. The expanding
market demand created opportunities for pharmaceutical
companies.

2 The population is aging gradually, and the burden of

long-term chronic diseases is increasing, which leads to the
increasing demand for therapeutic drugs in the market.
Aging weakens the immune system and increases a patient’s
susceptibility to infectious diseases. In addition, impaired
physical function increases the chance of developing other
diseases, such as cardiovascular disease and diabetes. Egypt
is undergoing a demographic transition, with the number of
people over 60 expected to more than double between 2020
and 2050, from 8.4 million (8% of the population) to 22 million
(14%).
Egyptian Pharmaceutical Market Dynamics - Opportunities Pharmaconex Market Research 29

3 Egypt is currently a member of the common market for Eastern and

southern Africa, the European Free Trade Association, GAFTA, Agadir, the
EU partnership and QIZ. In addition, Egypt also took the lead in signing the
trilateral free trade agreement, which integrates the three major African free
trade agreements - COMESA, SADC and EAC - and uses its price competitive
advantage over the international market to continuously develop the African
market.

4 According to Egypt’s 2030 vision, the Egyptian government is committed

to promoting the construction of a comprehensive medical insurance system.
In 2019, the National Medical Insurance Bureau (UHA) was newly established,
and the medical insurance funds will mainly come from the payment of the
insured. Individuals can pay 5% of the total salary to become the insured, and
also through IMF and other international organizations.

The new universal medical insurance system is planned to be implemented in

six stages. The first phase of 2020 starts from the pilot projects in six provinces,
and it is planned to complete full coverage by 2032. Egypt’s current president
Sisi is expected to be in power until 2030 after amending the constitution,
providing political guarantee for the promotion of universal health insurance,
and the future investment in health care is expected to continue to increase.
 Egyptian Pharmaceutical Market Dynamics - Risks Pharmaconex Market Research 30

Risks
• Insufficient product innovation and lack of international
qualification certification.

• Strong public centralized purchase and price reduction.

• There is no comprehensive medical insurance system, and drug sales are

based on out of pocket expenses.

• Bulk drugs are highly dependent on import.

• The production cost is high and the development potential is insufficient.

• Industrial policies favor domestic demand, resulting in weak exports.

• Surmount the regulatory obstacles of the economic environment - the delay

in the approval of government licenses, the lax implementation of intellectual
property rights, and poor pricing plans.

• Egypt’s currency devaluation and reform measures, such as cutting fuel

and energy subsidies and implementing the new value-added tax law,
have led to huge inflationary pressures.
 Pharmaconex Market Research 31

Part. 5
Egyptian APIs Market Forecast
Egyptian APIs Market Forecast - Revenue and Growth Rate Pharmaconex Market Research 32

Revenue and Growth Rate

Egypt APIs Revenue and Growth Rate (2022-2027) The Egypt APIs revenue will be
steadily increase in the future, and it
3500.00 3116.11 3252.76 7.00% is estimated to reach 3252.76 million
2723.73 2858.25 2999.72 USD in 2027. The growth rate has
3000.00 2602.73 6.00%
reached a peak in 2022, and it will
2500.00 5.00% gradually slow down in the next few
years.
2000.00 4.00%

1500.00 3.00%

1000.00 2.00%

500.00 1.00%

0.00 0.00%
2022 2023 2024 2025 2026 2027

Revenue (M USD) Growth Rate

Source: Secondary Sources, Expert Interviews and WK Information Research, 2022

Egyptian APIs Market Forecast - Revenue and Market Share by Type Pharmaconex Market Research 33

Revenue and Market Share by Type

Source: Secondary Sources, Expert Interviews and WK Information Research, 2022

Egyptian APIs Market Forecast - Revenue and Market Share by Application Pharmaconex Market Research 34

Revenue and Market Share by Application

Source: Secondary Sources, Expert Interviews and WK Information Research, 2022

Get in touch with us
Find out more about exhibiting and
sponsorship opportunities at Pharmaconex

Local & International Sales: China sales:

Samar Awad | Exhibition Manager Jennie Zhan| Account Manager
+2010 2444 5031 +86 138 284 18180
[email protected] [email protected]

India sales: Book a Stand at

Ms. Shruti Save Pharmaconex 2023
Mobile: +91 9773 4066 28
[email protected]

Mr. Sameer N. Matkar

Mobile : +91 986 7293 605
[email protected]

PharmaconexEgypt
Pharmaconex-egypt
Scan Me!
Contact Us
Public Relations: International Marketing: Membership Services:
[email protected] [email protected] [email protected]